Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA
January 10, 2018
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA – A Novel Treatment for Celiac Disease under Clinical Development TIMP-GLIA is designed to enable patients to develop tolerance to gluten...
Read More
Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease
August 21, 2017
Cour Pharmaceuticals, a specialty pharma company focused on autoimmune, allergic, and inflammatory diseases, announces that its Investigational New Drug (IND) for TIMP-GLIA is now open with the US Food &...
Read More
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease
December 8, 2015
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases Osaka, Japan, December 8, 2015, and Chicago, Ill., December 7, 2015 – Takeda Pharmaceutical Company...
Read More
Cour Pharma Presents Scientific Poster on Breakthrough Celiac Treatment at 16th Annual International Celiac Disease Symposium
December 3, 2015
Download Poster Here
Read More
Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease
October 19, 2015
Proprietary Antigen-specific Nanoparticles and Cure for Celiac Disease Chicago (June 22, 2015) – Cour Pharmaceutical Development Company today announced new data from a preclinical live animal study demonstrating a breakthrough...
Read More